Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California. more
Time Frame | INBX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -17.86% | 0.31% | -1.26% |
1-Month Return | -12.5% | 0.6% | -4.16% |
3-Month Return | -17.81% | -9.44% | -0.46% |
6-Month Return | -8.08% | -5.15% | 3.58% |
1-Year Return | -63.6% | 0.33% | 22.47% |
3-Year Return | -59.53% | 4.53% | 25.13% |
5-Year Return | -38.25% | 35.98% | 77.7% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 9.09M | 12.81M | 7.13M | 2.18M | 1.80M | [{"date":"2019-12-31","value":70.99,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":55.63,"profit":true},{"date":"2022-12-31","value":17,"profit":true},{"date":"2023-12-31","value":14.05,"profit":true}] |
Cost of Revenue | 47.91M | 73.50M | 2.69M | 2.85M | 1.19M | [{"date":"2019-12-31","value":65.18,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":3.66,"profit":true},{"date":"2022-12-31","value":3.87,"profit":true},{"date":"2023-12-31","value":1.62,"profit":true}] |
Gross Profit | (38.81M) | 12.81M | 7.13M | 2.18M | 609.00K | [{"date":"2019-12-31","value":-303.04,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":55.63,"profit":true},{"date":"2022-12-31","value":17,"profit":true},{"date":"2023-12-31","value":4.75,"profit":true}] |
Gross Margin | (426.86%) | 100.00% | 100.00% | 100.00% | 33.83% | [{"date":"2019-12-31","value":-426.86,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":33.83,"profit":true}] |
Operating Expenses | 52.81M | 80.25M | 83.69M | 131.29M | 219.83M | [{"date":"2019-12-31","value":24.02,"profit":true},{"date":"2020-12-31","value":36.51,"profit":true},{"date":"2021-12-31","value":38.07,"profit":true},{"date":"2022-12-31","value":59.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (43.71M) | (67.44M) | (76.56M) | (129.12M) | (219.22M) | [{"date":"2019-12-31","value":-4371400000,"profit":false},{"date":"2020-12-31","value":-6744300000,"profit":false},{"date":"2021-12-31","value":-7656400000,"profit":false},{"date":"2022-12-31","value":-12911700000,"profit":false},{"date":"2023-12-31","value":-21922100000,"profit":false}] |
Total Non-Operating Income/Expense | (12.51M) | (19.01M) | (10.42M) | (32.21M) | (40.43M) | [{"date":"2019-12-31","value":-1250700000,"profit":false},{"date":"2020-12-31","value":-1900700000,"profit":false},{"date":"2021-12-31","value":-1041800000,"profit":false},{"date":"2022-12-31","value":-3221300000,"profit":false},{"date":"2023-12-31","value":-4042600000,"profit":false}] |
Pre-Tax Income | (50.50M) | (75.63M) | (81.77M) | (145.22M) | (239.72M) | [{"date":"2019-12-31","value":-5050200000,"profit":false},{"date":"2020-12-31","value":-7563400000,"profit":false},{"date":"2021-12-31","value":-8176600000,"profit":false},{"date":"2022-12-31","value":-14522300000,"profit":false},{"date":"2023-12-31","value":-23972400000,"profit":false}] |
Income Taxes | 898.00K | 3.00K | 2.00K | 3.00K | 3.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":0.33,"profit":true},{"date":"2021-12-31","value":0.22,"profit":true},{"date":"2022-12-31","value":0.33,"profit":true},{"date":"2023-12-31","value":0.33,"profit":true}] |
Income After Taxes | (51.40M) | (75.64M) | (81.77M) | (145.23M) | (239.73M) | [{"date":"2019-12-31","value":-5140000000,"profit":false},{"date":"2020-12-31","value":-7563700000,"profit":false},{"date":"2021-12-31","value":-8176800000,"profit":false},{"date":"2022-12-31","value":-14522600000,"profit":false},{"date":"2023-12-31","value":-23972700000,"profit":false}] |
Income From Continuous Operations | (51.40M) | (76.12M) | (81.77M) | (145.23M) | (188.67M) | [{"date":"2019-12-31","value":-5140000000,"profit":false},{"date":"2020-12-31","value":-7612400000,"profit":false},{"date":"2021-12-31","value":-8176800000,"profit":false},{"date":"2022-12-31","value":-14522600000,"profit":false},{"date":"2023-12-31","value":-18867200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (51.40M) | (75.64M) | (81.77M) | (145.23M) | (241.36M) | [{"date":"2019-12-31","value":-5140000000,"profit":false},{"date":"2020-12-31","value":-7563700000,"profit":false},{"date":"2021-12-31","value":-8176800000,"profit":false},{"date":"2022-12-31","value":-14522600000,"profit":false},{"date":"2023-12-31","value":-24136100000,"profit":false}] |
EPS (Diluted) | - | (3.75) | (2.15) | (3.62) | (5.03) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-375,"profit":false},{"date":"2021-12-31","value":-215,"profit":false},{"date":"2022-12-31","value":-362,"profit":false},{"date":"2023-12-31","value":-503,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
INBX | |
---|---|
Cash Ratio | 4.45 |
Current Ratio | 4.70 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
INBX | |
---|---|
ROA (LTM) | -57.46% |
ROE (LTM) | -2031.05% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
INBX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.20 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.80 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
INBX | |
---|---|
Trailing PE | 0.12 |
Forward PE | NM |
P/S (TTM) | 121.93 |
P/B | 1.15 |
Price/FCF | NM |
EV/R | 7.15 |
EV/Ebitda | 0.01 |
Inhibrx Inc (INBX) share price today is $12.74
Yes, Indians can buy shares of Inhibrx Inc (INBX) on Vested. To buy Inhibrx Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INBX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Inhibrx Inc (INBX) via the Vested app. You can start investing in Inhibrx Inc (INBX) with a minimum investment of $1.
You can invest in shares of Inhibrx Inc (INBX) via Vested in three simple steps:
The 52-week high price of Inhibrx Inc (INBX) is $39.79. The 52-week low price of Inhibrx Inc (INBX) is $10.8.
The price-to-earnings (P/E) ratio of Inhibrx Inc (INBX) is 0.119
The price-to-book (P/B) ratio of Inhibrx Inc (INBX) is 1.15
The dividend yield of Inhibrx Inc (INBX) is 0.00%
The market capitalization of Inhibrx Inc (INBX) is $184.42M
The stock symbol (or ticker) of Inhibrx Inc is INBX